DOI QR코드

DOI QR Code

HER-2 Positive Breast Cancer - a Mini-Review

  • Asif, Hafiz Muhammad (University College of Conventional Medicine, Faculty of Pharmacy & Alternative Medicine, The Islamia University of Bahawalpur) ;
  • Sultana, Sabira (University College of Conventional Medicine, Faculty of Pharmacy & Alternative Medicine, The Islamia University of Bahawalpur) ;
  • Ahmed, Saeed (University College of Conventional Medicine, Faculty of Pharmacy & Alternative Medicine, The Islamia University of Bahawalpur) ;
  • Akhtar, Naheed (Department of Pharmacy, Faculty of Health & Medical Sciences, The University of Poonch) ;
  • Tariq, Muhammad (Margalla Institute of Health Sciences Rawalpindi)
  • Published : 2016.06.01

Abstract

Breast cancer is one of among all cancers with increased incidence, high mortality rate, and high economic and social costs. The the most common type of cancer among females worldwide, breast cancer is actually the uncontrolled proliferation of cells which attain malignancy. Recently it has shown that breast cancer contributes 11% among all types of cancer diagnosed globally on an annual basis and it is one of the leading causes of death among women. The human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine-protein kinase erbB-2 normally involved in the proliferation and division of breast cells. In some abnormal cases the HER2 gene does not work correctly and makes too many copies of itself. HER2-positive (HER2+) breast cancers constitute an aggressive type of breast cancer and tend to grow faster and are more likely to spread. However, therapies that specifically target HER2, such as Herceptin$^{(R)}$ (traztuzumab), are very effective. HER2 targeted therapies, has significantly improved the therapeutic outcome for patients with HER2 positive breast cancer.

Keywords

Breast cancer;HER2+;targeted therapy

References

  1. Aghdash SA, Ghojazadeh M, Gareh S Sheyklo, et al (2015). Breast Cancer Screening Barriers from the Woman’s Perspective: a Meta-synthesis. Asian Pac J Cancer Prev, 16, 3463-71. https://doi.org/10.7314/APJCP.2015.16.8.3463
  2. Albain KS, Allred DC, Clark GM (1994). Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr, 16, 35-42.
  3. Al-Dubai SA, Ganasegeran K, Alabsi AM, et al (2012). Exploration of barriers to breast-self examination among urban women in Shah Alam, Malaysia: a cross sectional study. Asian Pac J Cancer Prev, 13, 1627-32. https://doi.org/10.7314/APJCP.2012.13.4.1627
  4. Al-Naggar RA, Bobryshev YV (2012). Practice and barriers of mammography among Malaysian women in the general population. Asian Pac J Cancer Prev, 13, 3595-600. https://doi.org/10.7314/APJCP.2012.13.8.3595
  5. Arteaga CL, Sliwkowski MX, Osborne CK, et al (2012). Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol, 9, 16-32. https://doi.org/10.1038/nrclinonc.2011.177
  6. Asif HM, Sultana S, Akhtar N, et al (2014). Prevalence, Risk Factors and Disease Knowledge of Breast Cancer in Pakistan. Asian Pac J Cancer Prev, 15, 4411-6. https://doi.org/10.7314/APJCP.2014.15.11.4411
  7. Azim H, Azim HA, Escudier B (2009). Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 35, 633-8. https://doi.org/10.1016/j.ctrv.2009.06.007
  8. Bailey TA, Luan H, Clubb RJ, et al (2011). Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog, 10, 317-28.
  9. Baselga J, Albanell J, Molina MA, et al (2001). Mechanism of action of trastuzumab and scientific update. Semin Oncol, 28, 4-11. https://doi.org/10.1053/sonc.2001.22540
  10. Berkiten A, Sahin NH, Sahin FM, et al (2012). Meta analysis of studies about breast self examination between 2000-2009 in Turkey. Asian Pac J Cancer Prev, 13, 3389-97 https://doi.org/10.7314/APJCP.2012.13.7.3389
  11. Blackwell KL, Burstein HJ, Storniolo AM, et al (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol, 28, 1124-30. https://doi.org/10.1200/JCO.2008.21.4437
  12. Boyle P (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23, 7-12. https://doi.org/10.1093/annonc/mdr567
  13. Burstein HJ, Yan Sun Y, Dirix LY, et al (2010). Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol, 28, 1301-7. https://doi.org/10.1200/JCO.2009.25.8707
  14. Cameron D, Casey M, Press M, et al (2008). A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112, 533-43. https://doi.org/10.1007/s10549-007-9885-0
  15. Cetin I, Topcul (2014). M triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427-31 https://doi.org/10.7314/APJCP.2014.15.6.2427
  16. Chibon F, de Mascarel I, Sierankowski G, et al (2009). Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol, 22, 403-409. https://doi.org/10.1038/modpathol.2008.195
  17. Cobleigh MA, Vogel CL, Tripathy D et al (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639-48. https://doi.org/10.1200/JCO.1999.17.9.2639
  18. Cristofanilli M, Johnston SRD, Manikhas A, et al (2012). A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L + P) versus lapatinib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). ASCO Meeting Abstracts, 30, 531
  19. De Azambuja, Bedard E, Suter PL, et al (2009). Cardiac toxicity with anti HER 2 therapies: what have we learned so far? Target Oncol, 4, 39-41
  20. Fedenko K, Cortazar P, Keegan P, et al (2009). Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals [abstract]. J Clin Oncol, 27, 11520.
  21. Floriano-Sanchez E, Rodriguez NC, Bandala C, et al (2014). CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev, 15, 3805-9. https://doi.org/10.7314/APJCP.2014.15.8.3805
  22. Fouladi N, Pourfarzi F, Mazaheri E, et al (2013). Beliefs and behaviors of breast cancer screening in women referring to health care centers in northwest Iran according to the champion health belief model scale. Asian Pac J Cancer Prev, 14, 6857-62 https://doi.org/10.7314/APJCP.2013.14.11.6857
  23. Gianni L, Eiermann W Semiglazov V, et al (2014). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84.
  24. Gianni L, Dafni U, Gelber RD, et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-44. https://doi.org/10.1016/S1470-2045(11)70033-X
  25. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  26. Gradishar WJ (2012). HER2 therapy-an abundance of riches. N Engl J Med, 366, 176-8. https://doi.org/10.1056/NEJMe1113641
  27. Graus-Porta D, Beerli RR, Daly JM, et al (1997). ErbB-2, the preferredheterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 16, 1647-1655. https://doi.org/10.1093/emboj/16.7.1647
  28. Gurdal SO, Saraçoğlu VG, Oran ESO et al (2013). The Effects of Educational Level on Breast Cancer Awareness: A Cross- Sectional Study in Turkey. Asian Pac J Cancer Prev, 12, 295-300
  29. Hudis CA (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med, 357, 39-51 https://doi.org/10.1056/NEJMra043186
  30. Hui-LS, Xiao-Xin Dong, Cong YJ, et al (2015). Depression and the Risk of Breast Cancer: A Meta-Analysis of Cohort Studies. Asian Pac J Cancer Prev, 16, 3233-9. https://doi.org/10.7314/APJCP.2015.16.8.3233
  31. Konecny GE (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER 2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 66, 42-4.
  32. Lennon S, Barton C, Banken L, et al (2009). Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol, 27, 1685-93. https://doi.org/10.1200/JCO.2008.16.8351
  33. Lewis Phillips GD, Guangmin Li, Dugger DL, et al (2008). Cancer Res, 68, 9280-90. https://doi.org/10.1158/0008-5472.CAN-08-1776
  34. Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8. https://doi.org/10.7314/APJCP.2014.15.8.3353
  35. Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23, 4265-74. https://doi.org/10.1200/JCO.2005.04.173
  36. Mayer IA, Arteaga CL (2010). Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res, 16, 1355-7. https://doi.org/10.1158/1078-0432.CCR-09-3223
  37. Molina MA, Codony-Servat J, Albanell J, et al (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 61, 4744-9.
  38. National Comprehensive Cancer Network NCCN Practice Guidelines in Oncology. National Comprehensive Cancer Network [online] http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (2011).
  39. Erbil N, Bolukbas N (2012) Health beliefs and breast selfexamination among female university nursing students in Turkey. Asian Pac J Cancer Prev, 15, 6525-6529.
  40. O Donovan N, Byrne AT, O Connor AE, et al (2011). Synergistic interaction between trastuzumab and EGFR/HER 2 tyrosine kinase inhibitors in HER 2 positive breast cancer cells. Invest. New Drugs, 29, 752-759. https://doi.org/10.1007/s10637-010-9415-5
  41. Perez EA, Koehler M, Byrne J et al (2008). Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 83, 679-686. https://doi.org/10.1016/S0025-6196(11)60896-3
  42. Qi Yang, Hong-Yan Liu, Dan Liu, et al (2015). Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtype. Asian Pac J Cancer Prev, 16, 3229-32. https://doi.org/10.7314/APJCP.2015.16.8.3229
  43. Rabindran SK, Discafani CM, Rosfjord EC (2004). Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 64, 3958-65. https://doi.org/10.1158/0008-5472.CAN-03-2868
  44. Rimawi MF, Aleixo SB, Alarcon RA, et al (2012). A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). ASCO Meeting Abstracts, 30, 606.
  45. Ross JS, Fletcher JA (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist, 3, 237-252.
  46. Rubin I, Yarden Y (2001). The basic biology of HER2. Ann Oncol, 12, 13-8.
  47. Sauter G, Lee J, Bartlett JM, et al (2009). Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol, 27, 1323-33. https://doi.org/10.1200/JCO.2007.14.8197
  48. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
  49. Spector NL, Blackwell KL (2009). Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2 positive breast cancer. J Clin Oncol, 27, 5838-47. https://doi.org/10.1200/JCO.2009.22.1507
  50. Spector NL, Xia W, Burris H, et al (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol, 23, 2502-12. https://doi.org/10.1200/JCO.2005.12.157
  51. Tubbs R, Barlow WE, Budd GT, et al (2009). Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol, 27, 3881-3886. https://doi.org/10.1200/JCO.2008.20.1566
  52. Untch M, Muscholl M, Tjulandin S, et al (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol, 28, 1473-80. https://doi.org/10.1200/JCO.2009.21.9709
  53. Von Minckwitz, G du Bois A, Schmidt M, et al (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2 positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol, 27, 1999-2006. https://doi.org/10.1200/JCO.2008.19.6618
  54. Wardley AM, Xavier Pivot, Flavia MV, et al (2010). Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol, 28, 976-83. https://doi.org/10.1200/JCO.2008.21.6531
  55. Wolff AC, Hammond ME, Hicks DG, et al. (2013). J Clin Oncol, 31, 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
  56. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology; college of american pathologists. american society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
  57. Xia, W, Liu LH, Ho P, Spector NL (2004). Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 23, 646-53. https://doi.org/10.1038/sj.onc.1207166
  58. Xiu-Juan, Zha Q, Xin XY, et al (2014). Lack of Prognostic Value of Human Epidermal Growth Factor-Like Receptor 2 Status in Inflammatory Breast Cancer (IBC): a Meta-analysis. Asian Pac J Cancer Prev, 15, 9615-9. https://doi.org/10.7314/APJCP.2014.15.22.9615
  59. Yardley DA, Burris HA, Hanson S, et al (2009). Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer, 9, 178-83. https://doi.org/10.3816/CBC.2009.n.029
  60. Yerushalmi R, Gelmon K (2010). Treatment beyond progression: is it moving from belief to evidence? Oncologist, 15, 796-8. https://doi.org/10.1634/theoncologist.2010-0137
  61. Yin W, Jiang Y, Shen Z, et al (2011). Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One, 6, 21030. https://doi.org/10.1371/journal.pone.0021030
  62. Yusuf A, Ab Hadi IS, Mahamood Z, et al (2013). Understanding the breast cancer experience: a qualitative study of Malaysian women. Asian Pac J Cancer Prev, 14, 3689-98. https://doi.org/10.7314/APJCP.2013.14.6.3689
  63. Zainal NZ, Nik-Jaafar NR, Baharudin A, et al (2013). Prevalence of depression in breast cancer survivors: a systematic review of observational studies. Asian Pac J Cancer Prev, 14, 2649-56. https://doi.org/10.7314/APJCP.2013.14.4.2649
  64. Zubeda S, Kaipa PR, Shaik NA (2013). HER-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev, 14, 2231-5. https://doi.org/10.7314/APJCP.2013.14.4.2231

Cited by

  1. Early Diagnosis of Breast Cancer vol.17, pp.7, 2017, https://doi.org/10.3390/s17071572
  2. Targeted therapies in breast cancer: New challenges to fight against resistance vol.8, pp.2, 2017, https://doi.org/10.5306/wjco.v8.i2.120
  3. Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA-MB231 breast cancer cells vol.32, pp.9, 2018, https://doi.org/10.1002/ptr.6105
  4. Inhibition of Wnt3a/FOXM1/β-Catenin Axis and Activation of GSK3β and Caspases are Critically Involved in Apoptotic Effect of Moracin D in Breast Cancers vol.19, pp.9, 2018, https://doi.org/10.3390/ijms19092681
  5. Targeting HER2 in Nuclear Medicine for Imaging and Therapy vol.17, pp.1536-0121, 2018, https://doi.org/10.1177/1536012117745386
  6. Label-Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses vol.12, pp.3, 2018, https://doi.org/10.1002/prca.201700117
  7. Zr]pertuzumab in Response to T-DM1 Therapy pp.1557-8852, 2019, https://doi.org/10.1089/cbr.2018.2654